Jul 26, 2023 4:05pm EDT Tonix Pharmaceuticals Announces Accelerating Completion of Enrollment in Phase 2 UPLIFT Study of TNX-601 ER (Racemic Tianeptine) for Major Depressive Disorder: Topline Data Now Expected in Fourth Quarter 2023
Jul 24, 2023 7:00am EDT Tonix Pharmaceuticals Announces Data Supporting the Memory- and Cognition-Enhancing Effects of Racemic Tianeptine and (S)-Tianeptine, but not (R)-Tianeptine, in the In Vivo Rat Novel Object Recognition (NOR) Test
Jul 17, 2023 7:00am EDT Tonix Pharmaceuticals Announces Agreement and Initiation of Enrollment in Phase 2 Trial with the University of Washington to Study TNX-1900 (Potentiated Intranasal Oxytocin) for Social Anxiety Disorder
Jul 10, 2023 7:00am EDT Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 ‘POWER’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Pediatric Obesity
Jul 6, 2023 7:00am EDT Tonix Pharmaceuticals Comments on Two Long COVID Conferences Sponsored by the U.S. National Academies
Jul 3, 2023 7:00am EDT Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine Products
Jun 26, 2023 7:00am EDT Tonix Pharmaceuticals Enters into Agreement to Acquire Two FDA-Approved, Marketed Migraine Products from Upsher-Smith Laboratories, LLC
Jun 15, 2023 7:00am EDT Tonix Pharmaceuticals Announces Publication of Results from Phase 3 RELIEF Trial of TNX-102 SL for the Management of Fibromyalgia
